Parabilis Medicines cannot currently be evaluated on price-based measures due to a missing price feed, and the available fundamentals point to margin compression, insider selling, and below-average quality that argue for caution once trading data is restored.
Thesis pillars
- Value Trap Signals Margin And Insider Selling→Stable
- Data Outage Blocks Trade Setup→Stable
- Quality Concerns Flagged→Stable
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Jul 5, 2026· older than 90 days
Parabilis Medicines, Inc. (PBLS) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $27.44: Quality below floor (3.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 2.0:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 2.36; Below-average business quality.
Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that... Read more
Sell if holding. Engine safety override at $27.44: Quality below floor (3.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 2.0:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 2.36; Below-average business quality. Chart setup: RSI 51 mid-range, Bollinger mid-band. Score 5.3/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 116d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.
Recent developments
updated Nov 12, 2026Recent Developments — Parabilis Medicines, Inc.
Latest news
- NEWS Parabilis Medicines Reports Third Quarter 2026 Financial Results and Business Updates — fiscal.ai Nov 12, 2026
- NEWS Parabilis Medicines Q3 EPS $(0.36), Inline, Sales $2.114M Beat $375.000K Estimate — benzinga Nov 12, 2026 positive
- NEWS Canaccord Genuity Initiates Coverage On Parabilis Medicines with Buy Rating, Announces Price Target of $39 — benzinga Nov 9, 2026 positive
- NEWS Canaccord Genuity Initiates Coverage of Parabilis Medicines with Buy Rating — fiscal.ai Nov 9, 2026 positive
- NEWS Alphabet's Q3 13F Filing Reveals Parabilis Medicines Among Top Holdings — fiscal.ai Nov 6, 2026
Latest item Nov 12, 2026 · Generated 2026-11-22T11:57:10Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Volatile — 7.0% daily ATR makes tight stops impractical. Position-size conservatively.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $27.44: Quality below floor (3.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 2.0:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 2.36; Below-average business quality. Chart setup: RSI 51 mid-range, Bollinger mid-band. Prior stop was $25.52. Score 5.3/10, moderate confidence.
Analyst target: $35.67 (+30.0% upside). Prior stop was $25.52. Stop-loss: $25.52.
Quality below floor (3.0 < 4.0).
Parabilis Medicines, Inc. trades at a P/E of N/A (forward -11.6). TrendMatrix value score: 9.0/10. Verdict: Sell.
12 analysts rate PBLS, with a consensus score of 4.3/5. 6 analysts publish price targets averaging $41.
What does Parabilis Medicines, Inc. do?Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide...
Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, with a lead clinical program, FOG-001, that acts as a TCF-blocking beta-catenin inhibitor for cancer treatment. The company integrates artificial intelligence and data science into drug discovery, trial design, and clinical strategy optimization. Parabilis Medicines serves clients in the healthcare and life sciences industries, including clinical research organizations and medical professionals involved in oncology and cancer treatment. The company was founded in 2015 and is based in Cambridge, Massachusetts.